Evolent Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on March 27, 2017. The report details the entry into a material definitive agreement regarding an underwritten secondary public offering of the company's Class A common stock.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses exclusively on the terms of a secondary offering where selling stockholders, not the company, are the sellers of the shares.
Material Changes and Transaction Details
- Transaction Type: Underwritten secondary public offering of 7,500,000 shares of Class A common stock.
- Selling Stockholders: Certain affiliates of TPG Global, LLC, The Advisory Board Company, UPMC, and Ptolemy Capital, LLC.
- Underwriters: J.P. Morgan Securities LLC and Goldman, Sachs & Co. acted as representatives.
- Closing Date: The offering closed on March 31, 2017.
- Over-Allotment Option: Underwriters hold a 30-day option to purchase up to 1,125,000 additional shares from the selling stockholders.
- Proceeds: The filing text does not state the offering price per share or the total gross proceeds; however, as a secondary offering, proceeds are expected to go to the selling stockholders rather than the company.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. The primary risk disclosed relates to the customary representations, warranties, and indemnification provisions within the Underwriting Agreement. The document notes that the description of the agreement is subject to the full text filed as Exhibit 1.1.
Key Facts for Investor Verification
- Verify the offering price per share and total proceeds in the related Prospectus Supplement (not included in this text).
- Confirm the specific percentage of ownership being sold by each Selling Stockholder (TPG, Advisory Board, UPMC, Ptolemy).
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification liabilities and covenants.
- Monitor whether the underwriters exercise the 30-day option to purchase the additional 1,125,000 shares.